RNA interference: a chemist's perspective
- PMID: 20717561
- DOI: 10.1039/b920362c
RNA interference: a chemist's perspective
Abstract
Since the first unequivocal description of RNA interference (RNAi) in 1998, it has remained one of the hottest topics under investigation, culminating in the award of a Nobel Prize to its discoverers in 2006. Excitement over this technique derives from the ease with which it can be used to switch-off a specific gene in almost any organism, thereby allowing the role of that gene to be identified. More importantly, it offers the potential to treat certain diseases by switching-off the causative genes. Key to the RNAi pathway are the small-interfering RNAs (siRNAs), which at 21-23 nucleotides in length are very amenable to analogue development by chemists. However in comparison to the use of oligonucleotides as antisense agents, an area where many chemists first developed an interest in nucleic acids, the RNAi pathway is exceedingly complex. The literature is also complicated by the fact that the phenomenon has been studied in a wide range of organisms. In this tutorial review we have presented the subject from a more chemical perspective, incorporating a glossary to give a clear explanation of the specialist terms. However, the coverage of the biology remains sufficiently detailed to give the reader the necessary insight that we believe will be essential for the successful design of chemically modified siRNA.
Similar articles
-
Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.Early Hum Dev. 2009 Oct;85(10 Suppl):S31-5. doi: 10.1016/j.earlhumdev.2009.08.013. Epub 2009 Oct 14. Early Hum Dev. 2009. PMID: 19833462
-
An ESI-MS method for characterization of native and modified oligonucleotides used for RNA interference and other biological applications.Nat Protoc. 2008;3(3):351-6. doi: 10.1038/nprot.2007.535. Nat Protoc. 2008. PMID: 18323805
-
RNA interference and chemically modified small interfering RNAs.Curr Opin Chem Biol. 2004 Dec;8(6):570-9. doi: 10.1016/j.cbpa.2004.10.007. Curr Opin Chem Biol. 2004. PMID: 15556399 Review.
-
Short interfering RNA (siRNA): tool or therapeutic?Clin Sci (Lond). 2006 Jan;110(1):47-58. doi: 10.1042/CS20050162. Clin Sci (Lond). 2006. PMID: 16336204 Review.
-
State-of-the-art modified RNAi compounds for therapeutics.IDrugs. 2005 Aug;8(8):642-7. IDrugs. 2005. PMID: 16044372 Review.
Cited by
-
Surface Design Options in Polymer- and Lipid-Based siRNA Nanoparticles Using Antibodies.Int J Mol Sci. 2022 Nov 11;23(22):13929. doi: 10.3390/ijms232213929. Int J Mol Sci. 2022. PMID: 36430411 Free PMC article. Review.
-
Quantitative silencing of EGFP reporter gene by self-assembled siRNA lipoplexes of LinOS and cholesterol.Mol Pharm. 2012 Nov 5;9(11):3384-95. doi: 10.1021/mp300435x. Epub 2012 Oct 25. Mol Pharm. 2012. PMID: 23057412 Free PMC article.
-
Strategies, design, and chemistry in siRNA delivery systems.Adv Drug Deliv Rev. 2019 Apr;144:133-147. doi: 10.1016/j.addr.2019.05.004. Epub 2019 May 15. Adv Drug Deliv Rev. 2019. PMID: 31102606 Free PMC article. Review.
-
Optimization in Chemical Modification of Single-Stranded siRNA Encapsulated by Neutral Cytidinyl/Cationic Lipids.Front Chem. 2022 Mar 7;10:843181. doi: 10.3389/fchem.2022.843181. eCollection 2022. Front Chem. 2022. PMID: 35345539 Free PMC article.
-
Endoplasmic reticulum stress: molecular mechanism and therapeutic targets.Signal Transduct Target Ther. 2023 Sep 15;8(1):352. doi: 10.1038/s41392-023-01570-w. Signal Transduct Target Ther. 2023. PMID: 37709773 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources